Montmorillonite (MMt) is extensively applied as an efficient drug-carrier in designing drug delivery systems (DDS) due to its high specific surface area to load drugs. Modification of MMt via iron (Fe) blending can thus be a desirable method to improve its biocompatibility. Herein, magnetic nano-carriers involving the magnetic MMt (mMMt) core surrounded by chitosan (Chito) as a biopolymer and hyaluronic acid (HA) were prepared. To coat the mMMt fabricated through the coprecipitation of the Fe³⁺/Fe²⁺ ions in the presence of MMt, the acquired mMMt as the core was then treated with the Chito/HA solution to induce the cross-linked Chito/HA as the shell (namely, the Chito/HA-mMMt). The transmission electron microscopy (TEM) results accordingly revealed the existence of the mMMt inside the Chito/HA solution. Curcumin (CUR) and ciprofloxacin (CIP) were further employed as two model drugs. The CUR and CIP release from the Chito/HA-mMMt subsequently occurred in a sustained manner and pH-dependently. Additionally, an upsurge in the CUR and CIP release by applying an external magnetic field was observed. Thus, the prepared Chito/HA-mMMt hydrogels promise an outstanding potential performance in terms of expanding novel pH-dependent DDS with a sustained release behavior. The scratch assay of the given hydrogels also confirms their applications for wound healing.

This work aimed to fabricate a Cloisite 30B-incorporated carboxymethyl cellulose graft copolymer of acrylic acid and itaconic acid hydrogel (Hyd) via a free radical polymerization method for controlled release of Sunitinib malate anticancer drug. The synthesized samples were characterized by FTIR, XRD, TEM, and SEM-dot mapping analyses. The encapsulation efficiency of Hyd and Hyd/Cloisite 30B (6 wt%) was 81 and 93%, respectively, showing the effectiveness of Cloisite 30B in drug loading. An in vitro drug release study showed that drug release from all samples in a buffer solution with pH 7.4 was higher than in a buffer solution with pH 5.5. During 240 min, the cumulative drug release from Hyd/Cloisite 30B (94.97% at pH 7.4) is lower than Hyd (53.71% at pH 7.4). Also, drug-loaded Hyd/Cloisite 30B (6 wt%) demonstrated better antibacterial activity towards S. Aureus bacteria and E. Coli. High anticancer activity of Hyd/Cloisite 30B against MCF-7 human breast cancer cells was shown by the MTT assay, with a MCF-7 cell viability of 23.82 ± 1.23% after 72-hour incubation. Our results suggest that Hyd/Cloisite 30B could be used as a pH-controlled carrier to deliver anticancer Sunitinib malate.